Literature DB >> 1681168

Cholera in Africa: lessons on transmission and control for Latin America.

R I Glass1, M Claeson, P A Blake, R J Waldman, N F Pierce.   

Abstract

In January, 1991, epidemic cholera emerged in Peru and spread to 7 other countries of Latin America. Cholera was introduced 20 years ago to Africa, where it spread rapidly to 30 of the 46 countries of the region and by 1990 accounted for 90% of all cases reported to the World Health Organisation. Many lessons from the cholera epidemic in Africa are relevant to efforts to control the disease in Latin America. Public health practices from the past--quarantine and cordon sanitaire to halt introduction of cholera by travellers, and vaccination and mass chemoprophylaxis to control epidemics--are ineffective in preventing spread of the disease. Cholera can be transmitted not only by contaminated water but also by food. Social phenomena such as mass migrations and burial practices may play a greater role than previously understood. While efforts to prevent the spread of cholera have been ineffective, cholera-associated mortality can be decreased with rehydration therapy. Since the current pandemic is unlikely to retreat soon, new strategies are urgently needed to control the spread of cholera through sanitary and behavioural interventions or improved vaccines.

Entities:  

Keywords:  Africa; Americas; Antibiotics; Biology; Culture; Delivery Of Health Care; Demographic Factors; Developing Countries; Diarrhea--prevention and control; Diarrhea--transmission; Diseases; Drugs; Environment; Epidemics; Food Supply; Health; Health Services; Historical Survey; Immunization; Latin America; Migrants; Migration; Natural Resources; Oral Rehydration; Peru; Population; Population Dynamics; Primary Health Care; Refugees; Risk Factors; South America; Treatment; Vaccination

Mesh:

Year:  1991        PMID: 1681168     DOI: 10.1016/0140-6736(91)90673-d

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  25 in total

1.  Cholera in the Americas: an overview.

Authors:  J Sepulveda; H Gomez-Dantes; M Bronfman
Journal:  Infection       Date:  1992 Sep-Oct       Impact factor: 3.553

2.  Safety and immunogenicity in North Americans of a single dose of live oral cholera vaccine CVD 103-HgR: results of a randomized, placebo-controlled, double-blind crossover trial.

Authors:  K L Kotloff; S S Wasserman; S O'Donnell; G A Losonsky; S J Cryz; M M Levine
Journal:  Infect Immun       Date:  1992-10       Impact factor: 3.441

3.  Survival of Vibrio cholerae O1 on fomites.

Authors:  Israt Farhana; Zenat Zebin Hossain; Suhella Mohan Tulsiani; Peter Kjær Mackie Jensen; Anowara Begum
Journal:  World J Microbiol Biotechnol       Date:  2016-07-18       Impact factor: 3.312

4.  Anticipating the arrival of cholera from Latin America.

Authors:  S B Werner; G W Rutherford
Journal:  West J Med       Date:  1992-05

5.  Molecular characterization of Vibrio cholerae O1 strains isolated during cholera outbreaks in Guinea-Bissau.

Authors:  A Dalsgaard; H F Mortensen; K Mølbak; F Dias; O Serichantalergs; P Echeverria
Journal:  J Clin Microbiol       Date:  1996-05       Impact factor: 5.948

6.  Vibrio cholerae O1 El Tor: identification of a gene cluster required for the rugose colony type, exopolysaccharide production, chlorine resistance, and biofilm formation.

Authors:  F H Yildiz; G K Schoolnik
Journal:  Proc Natl Acad Sci U S A       Date:  1999-03-30       Impact factor: 11.205

7.  Corresponding type-specificity of vibriocidal and agglutinating activities of Vibrio cholerae antisera: relevance to vaccine immunogenicity.

Authors:  N W Preston
Journal:  Epidemiol Infect       Date:  1993-06       Impact factor: 2.451

Review 8.  Cholera.

Authors:  J B Kaper; J G Morris; M M Levine
Journal:  Clin Microbiol Rev       Date:  1995-01       Impact factor: 26.132

9.  Randomized, double-blind, placebo-controlled, multicentered trial of the efficacy of a single dose of live oral cholera vaccine CVD 103-HgR in preventing cholera following challenge with Vibrio cholerae O1 El tor inaba three months after vaccination.

Authors:  C O Tacket; M B Cohen; S S Wasserman; G Losonsky; S Livio; K Kotloff; R Edelman; J B Kaper; S J Cryz; R A Giannella; G Schiff; M M Levine
Journal:  Infect Immun       Date:  1999-12       Impact factor: 3.441

10.  A single dose of live oral cholera vaccine CVD 103-HgR is safe and immunogenic in HIV-infected and HIV-noninfected adults in Mali.

Authors:  R T Perry; C V Plowe; B Koumaré; F Bougoudogo; K L Kotloff; G A Losonsky; S S Wasserman; M M Levine
Journal:  Bull World Health Organ       Date:  1998       Impact factor: 9.408

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.